Trial Profile
A Randomized, Muticenter Double-blind Phase III Study of Neoadjuvant Pyrotinib Plus Trastuzumab and Docetaxel Compared With Placebo Plus Trastuzumab and Docetaxel in Women With HER2 Positive Early Stage or Locally Advanced Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 03 Aug 2023
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Pyrotinib (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer; Early breast cancer; HER2 positive breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms PHEDRA
- Sponsors Jiangsu Hengrui Medicine Co.
- 03 Aug 2021 Status changed from recruiting to active, no longer recruiting.
- 23 Jul 2018 New trial record
- 17 Jul 2018 Status changed from not yet recruiting to recruiting.